Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 10920190
Folding biological tissue via programmed cellular contractility
granted -
US 10920020
3D-printing of ultra-high refractive index polymers
granted -
US 10918738
Method of treating type I diabetes using an AAV vector encoding uracortin 2
granted -
US 10918673
Immunoisolation device
granted -
US 10918653
Bovine milk oligosaccharides
granted -
US 10918648
Estrogen receptor modulator combinations
granted -
US 10918598
On demand vesicle formation from vesicle precursors suitable for long-term storage
granted -
US 10918703
Fusion proteins for treating inflammatory diseases
granted -
US 10918732
Glycoconjugates and methods for their use
granted -
US 10912846
Molecular probes for chemiluminescence imaging and in vivo detection of target molecules
granted -
US 10912834
Topical formulations based on ionic species for skin treatment
granted -
US 10913957
Genetically modified MSC and therapeutic methods
granted -
US 10912767
Anthracycline prodrugs and methods of making and using the same
granted -
US 10912791
Compositions comprising antisense-encoded erythropoietin receptor and use thereof
granted -
US 10912860
Controllable self-annealing microgel particles for biomedical applications
granted -
US 10912764
Salinosporamides and methods of use thereof
granted -
US 10913726
Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them
granted -
US 10913750
Tubulin-binding compounds, compositions and uses related thereto
granted -
US 10912933
Implants for localized drug delivery and methods of use thereof
granted -
US 10912770
Targeting AMP deaminase 2 for ameliorating craving for sugar and other substances
granted -
US 10913798
Modulators of ROR1-ROR2 binding
granted -
US 10913790
Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules
granted -
US 10907158
Antisense antibacterial compounds and methods
granted -
US 10905736
Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism
granted -
US 10905721
Device and methods for platelet lysis or activation
granted -
US 10907124
Biomimetic membranes, methods of manufacture and uses thereof
granted -
US 10905770
Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
granted -
US 10899879
Biodegradable trehalose glycopolymers
granted -
US 10899839
Anti-Ryk antibodies and methods of using the same
granted -
US 10900043
Compositions and methods for treating bacterial disease
granted -
US 10899822
Compositions comprising D-amino acid peptides and methods of production and use thereof for inhibiting autoantibodies
granted -
US 10898595
Core-satellite nanocomposites for MRI and photothermal therapy
granted -
US 10898451
Methods of treating anti-NMDA receptor encephalitis with tramadol
granted -
US 10900973
Therapeutic antibodies against ROR-1 protein and methods for use of same
granted -
US 10899793
Melanocortin ligands and methods of use thereof
granted -
US 10899740
Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
granted -
US 10899738
Piperidines as menin inhibitors
granted -
US 10898497
Compositions and methods for cartilage repair
granted -
US 10897891
Compositions and methods for prolonged cell storage
granted -
US 10900054
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10898437
Formation of stable submicron peptide or protein particles by thin film freezing
granted -
US 10894061
Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells
granted -
US 10894044
Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
granted -
US 10894034
Anti-neoplastic compounds and methods targeting QSOX1
granted -
US 10894052
Heterocyclic inhibitors of ATR kinase
granted -
US 10894863
Cathode materials for Li—S batteries
granted -
US 10894065
Methods for production of platelets from pluripotent stem cells and compositions thereof
granted -
US 10889538
Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory